← Back to headlines
Roivant Outlines Brepocitinib Launch and Sarcoidosis Trial Timeline
Roivant has detailed plans for the launch of brepocitinib DM by the end of September and aims to release Phase III data for cutaneous sarcoidosis in 2028.
6 Aug, 20:26 — 6 Aug, 20:26
Sources
Showing 1 of 1 sources
